---
created: 2025-04-13
updated: 2025-04-13T10:53
id: x+u3d9t$O%
specialty: pharmaco
specialty_id: 541
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/firstaid::10-hematology-oncology::05-pharm::09-cancer-therapy-cell-cycle
  - "source/ak-step1-v11:": 
  - theme/firstaid::10-hematology-oncology::05-pharm::26-palbociclib
  - "source/ak-step1-v11:": 
  - source/ome-banner
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::08-antineoplastics::smallmoleculeinhibitors(tyrosinekinase-proteasomeinhibitors-cdkinhibitors)
  - "source/ak-step1-v11:": 
  - theme/uworld::10000-99999::15000-15999::15299
  - source/ak-step1-v11::^other::^expn::bgadd
  - source/ak-step1-v11::^other::^fa-updates::fa2018
  - source/ak-step1-v11::^other::^highyield::3-highyield-temporary"
type: flashcard
---

# Question
Palbociclib prevents cell cycle progression past the **G1 to S** restriction point through inhibition of CDKs 4 and 6 (ie, cyclin-dependent kinases), which normally regulate the movement of cells to this phase

---

# Answer
